Gastroesophageal Junction Carcinoma

subtype

Identifier: CI-CAN-00005404
Entity page: /cancer/gastroesophageal-junction-carcinoma ↗
Edges: 1,218

Neighbours: 15 genes18 drugs10 trials
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Gastroesophageal Junction Carcinoma approved for …APPROVED_FORderived15 of 19show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Gastric Adenocarcinoma	—	approved	Gastric Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification TrastuzumabFDA US 1998-09-2516 active / 28 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerRegulatoryapproved for Gastroesophageal Junction Adenocarcinoma (3 approval records)context: Gastric Adenocarcinoma
TP53 Mutation Chemotherapy5 active / 9 trials
Curatedlevel Bsensitivity· support 1civicObservedTP53 altered in 60% (309 / 518 cases, largest of 16 cohorts)no approval record in this cancercontext: Gastric Adenocarcinoma
ERBB2 Amplification Lapatinib0 active / 3 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma
MET Amplification Onartuzumab0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for MET in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma
ATM Underexpression Olaparib0 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedATM altered in 11% (56 / 518 cases, largest of 6 cohorts)no approval record in this cancercontext: Gastric Adenocarcinoma
EIF4EBP1 PHOSPHORYLATION Everolimus0 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for EIF4EBP1 in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma
FGFR1 Expression Infigratinib0 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for FGFR1 in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma
HSPH1 NUCLEAR EXPRESSION Cisplatin10 active / 33 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for HSPH1 in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Gastroesophageal Junction Carcinoma altered in cohorts of …ALTERED_INderived15 of 384show all (up to 200)
← altered in cohorts of	FER1L6 299 / 443 cases (67 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYC 296 / 443 cases (67 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 294 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 293 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DDX27 292 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 290 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ZNF831 290 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GSDMC 289 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NFATC2 289 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ANXA13 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHL38 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	WASHC5 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATAD2 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EXT1 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM91A1 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →

Gastroesophageal Junction Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 109show all (up to 200)
→ investigated in trials for	Oxaliplatinsmall molecule 87 trials (42 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	87	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 78 trials (32 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	78	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 58 trials (28 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 56 trials (31 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 55 trials (19 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 44 trials (19 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 38 trials (14 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 33 trials (10 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 28 trials (16 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 27 trials (9 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 26 trials (10 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 25 trials (16 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 19 trials (8 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 10 trials (5 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 10 trials (8 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Carcinoma	10	Observed	clinicaltrials	graph →

Gastroesophageal Junction Carcinoma studied in …STUDIED_INderived10 of 706show all (up to 200)
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07529808Phase 1/Phase 2 · recruiting Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03030404completed Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped ALIAS · 706 trials mapped (283 active)	—	—	Hereditary Gastric Diffuse Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06005493Phase 1/Phase 2 · recruiting Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · condition mapped ONTOLOGY_EXACT · 706 trials mapped (283 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →